Clinical Trial of BP1001 (L-Grb-2 Antisense Oligonucleotide) in CML, AML, ALL & MDS
Status:
Completed
Trial end date:
2017-03-30
Target enrollment:
Participant gender:
Summary
The first goal of this clinical research study is to find the highest safe dose of BP1001, a
liposomal Growth Factor Receptor Bound Protein-2 antisense oligodeoxynucleotide (L-Grb2 AS),
for patients with Philadelphia Chromosome positive CML, AML, ALL and MDS. The response of the
leukemia to this treatment will also be studied. The second goal of this clinical research
study is to evaluate the safety and toxicity of the combination of BP1001 and concurrent
low-dose ara-C (LDAC) in patients with AML.